Company news

DiaMedica Therapeutics Inc. news in 2025

DiaMedica Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

December 18, 2025

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

November 12, 2025

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 10, 2025

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

November 6, 2025

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 28, 2025

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

September 5, 2025

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

September 2, 2025

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 12, 2025

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

August 6, 2025

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

August 5, 2025

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

July 23, 2025

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

July 21, 2025

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

July 17, 2025

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

June 24, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 22, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 19, 2025

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 13, 2025

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 8, 2025

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

May 7, 2025

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

March 17, 2025

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

March 11, 2025

DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors

February 24, 2025

DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

February 20, 2025

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 9, 2025

Calls in 2025

Decks in 2025